Prima BioMed Total Assets 2010-2021 | IMMP
Prima BioMed total assets from 2010 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Prima BioMed Annual Total Assets
(Millions of US $) |
| 2021 |
$61 |
| 2020 |
$31 |
| 2019 |
$29 |
| 2018 |
$36 |
| 2017 |
$26 |
| 2016 |
$31 |
| 2015 |
$26 |
| 2014 |
$21 |
| 2013 |
$34 |
| 2012 |
$43 |
| 2011 |
$57 |
| 2010 |
$17 |
| 2009 |
$2 |
Prima BioMed Quarterly Total Assets
(Millions of US $) |
| 2017-03-31 |
$27 |
| 2016-12-31 |
$29 |
| 2016-06-30 |
$31 |
| 2015-12-31 |
$37 |
| 2015-06-30 |
$26 |
| 2014-12-31 |
$34 |
| 2014-06-30 |
$21 |
| 2013-12-31 |
$30 |
| 2013-06-30 |
$34 |
| 2012-12-31 |
$34 |
| 2012-06-30 |
$43 |
| 2011-06-30 |
$57 |
| 2010-06-30 |
$17 |
| 2009-06-30 |
$2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.209B |
$0.003B |
|
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
|
